Microdeletion syndrome

Numares Health and Mayo Clinic Strengthening Collaboration for Improved Diagnostic Tests

Retrieved on: 
Thursday, November 3, 2022
Biomarker, FDA, Patient, Health, Technology, Multimedia, Metabolomics, Research, Mayo Clinic, Physician, View, Diagnosis, NMR, Algorithm, Microdeletion syndrome, HIV disease progression rates, Pathology, Conditional sentence, Liver, Kidney, MGS, Machine learning, Medical device, Pharmaceutical industry, Medical imaging, Christopher Numar of Forli

The expanded collaboration builds on Mayo Clinic's clinical research support for Numares Health to include an innovative convertible equity investment.

Key Points: 
  • The expanded collaboration builds on Mayo Clinic's clinical research support for Numares Health to include an innovative convertible equity investment.
  • Numares is a German health care diagnostics company founded nearly two decades ago with its U.S. headquarters recently moved to The Woodlands, Texas.
  • "The expanded research collaboration and financial investment in Numares will help us further understand this new and potentially disruptive test modality, develop new diagnostic tests and enable Mayo Clinic to better serve our patients and physicians."
  • Numares Health is a health care company using AI-enabled technology to develop novel diagnostic tests to help physicians improve care for their patients with chronic diseases, including kidney, cardiovascular, liver and neurologic conditions.

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), Marketing, Growth, Government budget balance, Method, Infection, U.S. Securities and Exchange Commission, Fragile X syndrome, Schizophrenia, Annual report, GLOBE, Royal commission, Patent, Risk, Nasdaq, COVID-19, Down syndrome, European Commission, DiGeorge syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chromosome, Form 10-K, Anxiety, Prizes as an alternative to patents, ASD, Company, Private Securities Litigation Reform Act, European Medicines Agency, FDA, Skin, Ventricular septal defect, Communication, Patient, Food, United Kingdom, FXS, Fast Track, Autism, Binary relation, Microdeletion syndrome, ADHD, Pharmaceutical industry, Jean-François Zygel, EU, Cannabidiol

11,458,109, titled Treatment of 22q11.2 Deletion Syndrome With Cannabidiol, which includes claims directed to methods of treating one or more behavioral symptoms of 22q11.2 deletion syndrome with cannabidiol.

Key Points: 
  • 11,458,109, titled Treatment of 22q11.2 Deletion Syndrome With Cannabidiol, which includes claims directed to methods of treating one or more behavioral symptoms of 22q11.2 deletion syndrome with cannabidiol.
  • This new patent, which expires in 2040, is part of an expanding international intellectual property portfolio covering the Companys transdermal cannabidiol product candidate, Zygel.
  • There are currently seven corresponding U.S. patents and one corresponding EU patent related to methods of treating Fragile X syndrome, 22q11.2 deletion syndrome or autism spectrum disorder.
  • Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS), 22q11.2 deletion syndrome (22q) and autism spectrum disorder (ASD).

FibroGen to Participate at Stifel 2022 Healthcare Conference

Retrieved on: 
Tuesday, November 1, 2022
Pancreatic cancer, Duchenne, MDS, Duchenne muscular dystrophy, IPF, Conference, GLOBE, Idiopathic pulmonary fibrosis, Research, Dialysis, HIF, DMD, Anemia, CTGF, NASDAQ, CIA, Company, CKD, Patient, Biology, SAN, Therapy, LAPC, Microdeletion syndrome, Pharmaceutical industry, Roxadustat

SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY taking place on November 15, at 1:50 PM Eastern Time.

Key Points: 
  • SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY taking place on November 15, at 1:50 PM Eastern Time.
  • A live audio webcast of the event will be available on the Events & Presentations section of the FibroGen Investors webpage at www.fibrogen.com.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space.

F33 Adopts Open Source Service Level Objective Development Lifecycle (SLODLC) to Deliver Cloud Reliability and Migration Services

Retrieved on: 
Wednesday, November 2, 2022
Data Management, Security, Technology, Software, Artificial Intelligence, Internet, Cloud, Virtusa, Trusted Shops, CEO, Microdeletion syndrome, OutSystems, Partnership, Service level, Accenture, Organization, Shop, Etsy, COO, Compliance, Object (computer science), Machine learning, MLOps, IAG, Ford Motor Company, Furo, SLO, Risk management, Cognizant, Oracle, F33

F33, a SLODLC contributor , today announced they are adopting the Service Level Objective Development Lifecycle (SLODLC) as part of their core practice to accelerate cloud migration and cloud growth with improved reliability and software delivery.

Key Points: 
  • F33, a SLODLC contributor , today announced they are adopting the Service Level Objective Development Lifecycle (SLODLC) as part of their core practice to accelerate cloud migration and cloud growth with improved reliability and software delivery.
  • Introduced in May 2022, the SLODLC community is quickly moving to become the standard adoption methodology for Service Level Objectives (SLOs) and their scalable deployment.
  • Along with F33, SLODLC members include leading companies with early contributors, including Accenture, Cognizant, Etsy, Ford Motor Company, Furo, IAG, Oracle, OutSystems, Trusted Shops, and Virtusa.
  • SLOs help companies better quantify user expectations, deliver technology services efficiently, and better manage the inherent tradeoffs in building a digital business.

Nobl9 Introduces Replay to Set Service Level Objectives Based on Historical Data

Retrieved on: 
Tuesday, November 1, 2022
Professional Services, Data Management, Technology, Data Analytics, Software, Internet, Goal, Microdeletion syndrome, Automation, OutSystems, CPO, Service-level objective, Observability, Time, Graphite, SLI, Datadog, Amazon, Budget, SLO, Satellite navigation device, Online shopping, Risk management, Prometheus, Splunk

Nobl9 makes the handshake-agreement between platform teams and application teams explicit in code, said Brian Singer, co-founder and CPO at Nobl9.

Key Points: 
  • Nobl9 makes the handshake-agreement between platform teams and application teams explicit in code, said Brian Singer, co-founder and CPO at Nobl9.
  • Now with Replay, our customers can ask what if we had set different goals for our service?
  • and see the results based on accurate past data so they dont have to guess or wait for new data to accumulate.
  • We received early access to Replay, and were amazed by how fast we can create and iterate on our service level objectives (SLOs) across many data sources.

SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Term Catalysts

Retrieved on: 
Monday, October 31, 2022
Manifest and latent functions and dysfunctions, Safety, Death, Inflammation, AKI, Nasdaq, Design history file, Failure, Forward-looking statement, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, Risk, Private Securities Litigation Reform Act, Acquisition, NASDAQ, Monocyte, Environment, Science, University, Cytokine, Medicine, Patient, Disease, GLOBE, Population, Acute respiratory distress syndrome, CKD, Humanitarian Device Exemption, Solution, LMAO, SEC, Form, Homeostasis, Neutrophil, Mortality, SCD, FDA, Therapy, COVID-19, Trial of the century, Food, HDE, Physician, CKRT, SeaStar, Adult, Company, Growth, Acute kidney injury, Microdeletion syndrome, Jean-Louis Vincent, Chronic kidney disease, Pharmaceutical industry

Denver, Colorado, Oct. 31, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced the commencement of trading on the Nasdaq Capital Market under the ticker symbol “ICU” having successfully completed its previously announced definitive agreement for a business combination transaction with LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company. The Company also provided a business outlook and outlined key upcoming milestones.

Key Points: 
  • SeaStar Medical has continued to deliver on its promises with operational excellence.
  • In addition to the progress weve made on the corporate front, we continue to advance our innovative SCD therapy platform.
  • I am excited for what is to come and look forward to providing updates as we execute on the milestones ahead.
  • Denver-based SeaStar Medical (Nasdaq: ICU) is a medical technology company that is focusing on redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs.

Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219

Retrieved on: 
Monday, October 31, 2022
Board, Safety, Natural history, Drug Quality and Security Act, PD, Securities Act of 1933, Securities Exchange Act of 1934, Insulin, Research, Cancer, Association, Degenerative disease, U.S. Securities and Exchange Commission, Patient, SEC, Pancreas, Health Canada, CTA, Type 2 diabetes, Risk, Securities and Exchange Commission (Philippines), Adult, Phase, Microdeletion syndrome, Disease, GLOBE, PK, Doctor of Philosophy, Growth, FDA, IND, Harvard Medical School, Hyperglycemia, European Association for the Study of Diabetes, Regeneration, Nasdaq, Pharmacokinetics, Pharmaceutical industry, Diabetes

Biomea has completed the Phase I portion of the trial in healthy volunteers.

Key Points: 
  • Biomea has completed the Phase I portion of the trial in healthy volunteers.
  • With the dosing of our first patient with BMF-219, we have reached an important milestone for the nearly 500 million patients worldwide with type 2 diabetes.
  • With the completion of the Phase I portion in healthy volunteers, we have now swiftly progressed to dosing type 2 diabetes patients in the Phase II.
  • Phase II consists of multiple ascending dose cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.

Vive Funds' Veena Jetti Shares Importance of Diversity for Global Diversity Month

Retrieved on: 
Monday, October 31, 2022
Leadership, Male, Policy, National, Woman, Family, Workplace, Female, Industry, Interview, Investment, Parent, GLOBE, Microdeletion syndrome, Trial balance, Workforce, Feedback, Parental leave, Job satisfaction, Mentorship, Face, Bank, Management

The feature interview is a part of a series of pieces by National Today in celebration of Global Diversity Awareness Month.

Key Points: 
  • The feature interview is a part of a series of pieces by National Today in celebration of Global Diversity Awareness Month.
  • Jetti has found that many companies need to be made aware that they are plagued by poor diversity and inclusion practices.
  • To learn more about Vive Funds or founder Veena Jetti, please visit https://vivefunds.com .
  • Vive has developed a rich network of global business partners to make early and transformational investments in assets that have the potential to do great things.

European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Retrieved on: 
Monday, October 31, 2022
Safety, NINDS, Leber's hereditary optic neuropathy, Vomiting, LHON, JAMA Network Open, Vamorolone, Microdeletion syndrome, EC, Vitamin D deficiency, Cystic fibrosis, CMO, Dissociative, Patient, UK, Time, Foundation, EMA, JAMA, NCATS, Review, JAMA Neurology, Committee for Medicinal Products for Human Use, DMD, European Medicines Agency, Orphan drug, Food and Drug Administration Amendments Act of 2007, Life Science Alliance, CHMP, FDA, National, Defense, National Institutes of Health, Adolescence, Food, PIM, NIAMS, NDA, Muscular dystrophy, Company, Duchenne muscular dystrophy, Union, European Commission, MAA, Vaccine, Pharmaceutical industry, Wood drying, MD, Duchenne

Pratteln, Switzerland, October 31, 2022 Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD).

Key Points: 
  • Pratteln, Switzerland, October 31, 2022 Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD).
  • Subject to EC approval, expected later in 2023, vamorolone will receive marketing authorization in all member states of the European Union, as well as in Norway, Liechtenstein and Iceland.
  • Santhera has submitted a new drug application (NDA) to the U.S. FDA and a marketing authorization application (MAA) to the European Medicines Agency (EMA) for vamorolone for the treatment of DMD.
  • ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders.

Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial

Retrieved on: 
Monday, October 31, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, People, Hepatomegaly, Beta thalassemia, Safety, Hypertension, Myelodysplastic syndrome, Deep vein thrombosis, DBP, History, MDS, Splenomegaly, SBP, EMH, Patient, The Bristol-Myers Squibb Children's Hospital, BMY, RBC, NYSE, Risk, Stroke, ESA, Spinal cord compression, Adult, Clinical trial, Anemia, Acquisition, Iron overload, Embolism, HB, Lymphatic system, Merck, Portal vein thrombosis, Bristol Myers Squibb, Microdeletion syndrome, Incidence, TEE, Splenectomy, Thrombosis, Hormone replacement therapy, Pharmaceutical industry, Blood product

We are pleased with the positive results of the COMMANDS study and look forward to presenting these important data.

Key Points: 
  • We are pleased with the positive results of the COMMANDS study and look forward to presenting these important data.
  • Bristol Myers Squibb will complete a full evaluation of the COMMANDS data and work with investigators to present detailed results at an upcoming medical meeting, as well as discuss these results with health authorities.
  • Bristol Myers Squibb thanks the patients and investigators who are participating in the COMMANDS clinical trial.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .